During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
Keywords: COVID-19; Casirivimab; Imdevimab; Immunocompromised; Monoclonal antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.